Evaluating a Therapeutic Agent That May Inhibit a Protein Associated with Lymphoma
This study evaluates a new therapeutic agent designed to inhibit the survivin protein in canine lymphoma.
This study evaluates a new therapeutic agent designed to inhibit the survivin protein in canine lymphoma.
This study investigates the role of citrullination in canine mammary cancer and how interfering with this process might lead to more effective anticancer treatments.
This study will determine the genetic and functional differences of eight genes that are strongly associated with congenital extrahepatic portosystemic shunts in several small dog breeds.
This study investigates the effects of topical ophthalmic prednisolone (steroid) and diclofenac (nonsteroidal anti-inflammatory drug) on diabetes mellitus regulation in client-owned dogs.
This study will characterize the expression of toll-like receptors, which activate the immune system, in canine osteosarcoma cells to better determine the biological consequences associated with activating these receptors.
Investigators are assessing the potential for a specific tumor-cell population in canine hemangiosarcoma to sequester drugs within their lysosomes as a novel mechanism of drug resistance.
The goal of this study is to determine new strategies for treating canine mast cell tumors based on the targeting of a DNA-packaging protein called NDY1.